Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Northwest Bio CEO Interviewed On Floor Of New York Stock Exchange

|Includes: Northwest Biotherapeutics, Inc. (NWBO)

NWBO LogoNorthwest Biotherapeutics (NasdaqCM: NWBO) CEO Linda Powers was recently interviewed on the floor of the New York Stock Exchange by Fox Business, the Huffington Post, and the International Business Times.

In the Fox interview, Ms. Powers described the importance of NW Bio's DCVax cancer immunotherapy platform in mobilizing a patient's whole immune system, and in targeting the full set of biomarkers on the cancer. You can watch the interview at

In the Huffington Post and New York Financial Press interview, Ms. Powers outlined in more detail the process of creating the DCVax vaccine. She also discussed the significance of key regulatory approvals obtained in the U.S. and Europe, relating to Phase III clinical trials and Phase I/II trials. You can watch the Huffington Post interview at

In the International Business Times interview, Ms. Powers recounted the cost-saving potential of the DCVax platform, which positions NW Bio well in the face of the rapidly rising costs of less-effective conventional cancer treatments. You can watch the interview at

NWBO's lead program is a 312-patient Phase III trial to treat glioblastoma multiforme, the most aggressive and lethal form of brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer and Phase I/II trials in multiple other cancers. NWBO's cancer therapies have demonstrated the ability to significantly extend patient survival while eliminating the debilitating side effects associated with conventional treatments such as chemotherapy. To learn more about NWBO, watch our "Money Report" interview with CEO Linda Powers.

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit